📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-05 17:01
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
30 announcements match the current filters (relevance ≥ 5).
Medanta Q1 FY27: 26% Revenue Growth to ₹1,326 Cr; Noida EBITDA Loss Shrinks to ₹4.9 Cr
Medanta (Global Health) delivered a strong Q1 FY27 with revenue growing 26% YoY to ₹1,326.2 Cr, supported by a 28% surge in inpatient volumes. While reported PAT of ₹157.3 Cr was slightly lower YoY due to a ₹19.6 Cr one-time gain in the base quarter, operational EBITDA grew 23% to ₹315.3 Cr. A key highlight is the Noida facility, which saw its EBITDA loss narrow significantly to ₹4.9 Cr from ₹23.6 Cr in the previous quarter, signaling an earlier-than-expected breakeven.
Confidence: HIGH
What changedThe Noida facility has ramped up significantly faster than expected, and the Guwahati project has been upsized to 650 beds.
Why it mattersFaster turnaround of new hospitals like Noida reduces margin drag, while the upsized Guwahati project indicates strong demand and aggressive growth intent in the Northeast.
Q1 Revenue: ₹1,326.2 CrNoida EBITDA Loss: ₹4.9 CrARPOB: ₹70,244Operational Beds: 3,737International Revenue: ₹78.2 Cr
📅 Short termPositive sentiment is expected as the narrowing losses at Noida and strong volume growth suggest robust operational momentum.
📈 Long termStructural growth remains strong with a 2,000-bed expansion pipeline and a shift toward higher-margin complex quaternary care.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks in large-scale greenfield projects
- Potential margin dilution during the initial gestation of new bed additions
Key Highlights
Consolidated income rose 26% YoY to ₹1,326.2 Cr, representing approximately 30% of TTM revenue in a single quarter.
Noida facility revenue jumped 63% QoQ to ₹85.5 Cr, with EBITDA loss narrowing by 79% to ₹4.9 Cr.
Network ARPOB (Average Revenue Per Occupied Bed) increased 5% YoY to ₹70,244.
International patient revenue grew 23% YoY to ₹78.2 Cr despite geopolitical tensions.
Guwahati expansion project capacity was scaled up to 650 beds from previous plans.
👀 What to Watch
Monitor the Noida facility for EBITDA breakeven in the next 1-2 quarters and track the execution timeline of the 2,000-bed greenfield expansion in Mumbai and Delhi.
26% Revenue Growth in Q1 FY27; Medanta Noida EBITDA Loss Narrows to ‡4.9 Cr
Global Health (Medanta) delivered a robust Q1 FY27 with total income rising 26.2% YoY to ‡1,326.2 cr, driven by a 27.7% surge in inpatient volumes. While reported PAT saw a marginal 1.1% dip to ‡157.3 cr, this was primarily due to a ‡19.6 cr exceptional gain in the base year (Q1 FY26). A critical positive is the Noida facility's performance, where revenue reached ‡85.5 cr and EBITDA losses narrowed significantly to ‡4.9 cr from ‡23.6 cr in the preceding quarter. Operational efficiency remained high with ARPOB increasing 5.5% to ‡70,244 and Average Length of Stay (ALOS) improving to 2.87 days.
Confidence: HIGH
What changedMedanta has demonstrated a significant operational turnaround at its Noida facility and maintained strong double-digit volume growth across its network.
Why it mattersThe narrowing losses in Noida and robust volume growth validate the company's ability to scale new large-format hospitals while maintaining high realizations (ARPOB).
Q1 Total Income: ‡1,326.2 crIncome vs TTM Revenue: 30.07%Noida EBITDA Loss: ‡4.9 crARPOB: ‡70,244International Patient Revenue: ‡78.2 crOPD Pharmacy Revenue Growth: 50.9%
📅 Short termThe stock is likely to react positively to the strong volume growth and the near-breakeven status of the Noida hospital, which has been a drag on margins.
📈 Long termStructural growth is supported by a clear 2,000-bed expansion pipeline and increasing contribution from high-margin international patients and pharmacy retail.
⚠ Risk flags
- Gestation risks for upcoming greenfield projects in Mumbai and Delhi
- Intense competition in the NCR region impacting occupancy
Key Highlights
Total Income reached a record ‡1,326.2 cr, representing 26.2% YoY growth.
In-patient volumes grew 27.7% to 60,214, while Out-patient volumes rose 34.5% to 11,00,928.
Noida hospital EBITDA loss reduced to ‡4.9 cr from ‡23.6 cr in Q4 FY26, nearing operational breakeven.
Average Revenue Per Occupied Bed (ARPOB) improved 5.5% YoY to ‡70,244.
Added 72 new beds in Q1 (51 in Noida, 21 in Lucknow), taking total installed capacity to 3,737 beds.
👀 What to Watch
Watch for the Noida facility to turn EBITDA positive in H1 FY27 and monitor the execution timeline of the 2,000-bed greenfield expansion across Mumbai, Delhi, and Guwahati.
26.2% Revenue Growth in Q1 FY27; Medanta Scales Guwahati Project to 650 Beds
Medanta reported its highest-ever quarterly total income of ₹1,326.2 cr, a 26.2% YoY increase, driven by robust volume growth with in-patient counts rising 27.7%. EBITDA grew 23.5% to ₹315.3 cr, although margins slightly contracted by 51 bps to 23.8% due to the ramp-up of the Noida facility. Profit After Tax (PAT) was nearly flat at ₹157.3 cr, primarily because the base quarter (Q1 FY26) included a ₹19.6 cr one-time exceptional gain. Operationally, ARPOB improved 5.5% to ₹70,244, and the company announced a significant scale-up of its Guwahati greenfield project to 650 beds with a ₹970 cr capex.
Confidence: HIGH
What changedMedanta achieved record quarterly revenue and significantly increased the scope of its Guwahati expansion from previous plans.
Why it mattersThe results demonstrate strong demand for tertiary care and successful ramp-up of new units like Noida, while the Guwahati expansion signals aggressive long-term growth intent.
Total Income (Q1 FY27): ₹1,326.2 crYoY Revenue Growth: 26.2%ARPOB: ₹70,244Guwahati Capex: ₹970 crGuwahati Capex vs Net Worth: ~24.2%Beds added in Q1: 72 units
📅 Short termPositive sentiment is expected as the company shows strong top-line momentum and narrowing losses in its newest major facility (Noida).
📈 Long termStructural growth is supported by a massive 2,950-bed expansion pipeline, which represents nearly 80% of current installed capacity, targeting high-growth regions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin pressure from new hospital ramp-ups
- Execution risks in large-scale greenfield projects
- High employee benefit expenses which rose 33.3% YoY
Key Highlights
Total Income reached a record ₹1,326.2 cr, representing 26.2% YoY growth.
Noida facility EBITDA loss narrowed significantly to ₹4.9 cr from ₹23.6 cr in Q4 FY26.
Guwahati project capacity increased to 650 beds with a total planned capex of ₹970 cr.
International patient revenue grew 23.0% YoY to ₹78.2 cr.
Network-wide bed capacity reached 3,737 installed beds as of June 30, 2026.
👀 What to Watch
Monitor the EBITDA break-even timeline for the Noida facility and the execution progress of the 2,950-bed expansion pipeline across five greenfield projects.
Medanta Q1 Revenue Up 22%; Guwahati Hospital Capacity Expanded to 650 Beds (Rs 970 Cr Capex)
Global Health Limited (Medanta) reported a 22.3% YoY increase in standalone revenue to Rs 1,078.72 cr for Q1 FY27. While standalone PAT declined 9.6% to Rs 137.31 cr, this was primarily due to a high base in the previous year which included an exceptional gain. A major highlight is the upward revision of the Guwahati hospital project from 400 to 650 beds, involving a total investment of Rs 970 cr. The company also fixed August 14, 2026, as the record date for a Rs 0.50 per share final dividend.
Confidence: HIGH
What changedThe planned Guwahati hospital project has been significantly upsized from 400 to 650 beds due to revised building bye-laws and increased FSI.
Why it mattersThe Rs 970 cr investment in Guwahati is a major expansion that will add approximately 17% to the company's current total bed capacity, targeting a high-demand region with limited tertiary care.
Q1 Standalone Revenue: Rs 1,078.72 crGuwahati Project Capex: Rs 970 crCapex vs Net Worth: 24.17%Revised Guwahati Bed Capacity: 650 bedsDividend per share: Rs 0.50
📅 Short termThe strong revenue growth and significant expansion announcement are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe expansion into Guwahati and Noida, totaling over 2,000 planned beds, aligns with the company's 15% growth strategy and strengthens its tertiary care leadership.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk over the 3-4 year construction timeline
- Potential margin pressure during the gestation period of new large-scale facilities
Key Highlights
Standalone revenue for Q1 FY27 grew to Rs 1,078.72 cr from Rs 882.16 cr YoY
Guwahati hospital capacity upsized by 250 beds to a total of 650 beds
Estimated investment for the Guwahati project is Rs 970 cr, representing ~24% of current Net Worth
Final dividend of Rs 0.50 per share announced with a record date of August 14, 2026
Total existing bed capacity across the group stands at 3,737 as of June 30, 2026
👀 What to Watch
Monitor the execution timeline of the Guwahati project over the next 3-4 years and the ramp-up of the recently acquired Indore oncology facility.
Medanta Upsizes Guwahati Hospital to 650 Beds with Rs 970 Cr Investment; Q1 Revenue Up 22% YoY
Global Health Limited (Medanta) has significantly revised its Guwahati hospital plan, increasing capacity from 400 to 650 beds with an estimated investment of Rs 970 Cr. This expansion represents approximately 24% of the company's current net worth, targeting the underserved Northeast market. For Q1 FY27, the company reported standalone revenue of Rs 1,078.7 Cr, a 22.3% increase YoY. Additionally, a final dividend of Rs 0.50 per share has been confirmed with a record date of August 14, 2026.
Confidence: HIGH
What changedThe planned Guwahati hospital project was upsized from 400 to 650 beds due to increased FSI and revised local building bylaws.
Why it mattersThis is a major capital commitment (Rs 970 Cr) that strengthens Medanta's presence in Northeast India, a region with high demand for tertiary care and a catchment area of 50 million people.
Guwahati Bed Capacity: 650 bedsProject Cost: Rs 970 CrCapex vs Net Worth: ~24.2%Q1 Standalone Revenue: Rs 1,078.7 CrExisting Bed Capacity: 3,737 bedsDividend per share: Rs 0.50
📅 Short termThe stock may react positively to the aggressive expansion plans and steady double-digit revenue growth in the quarterly results.
📈 Long termThe addition of 650 beds in a strategic regional hub like Guwahati, alongside the 2,000-bed pipeline in Mumbai and Delhi, provides a clear multi-year growth trajectory.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk over the 3-4 year construction period
- Potential margin pressure during the initial gestation phase of new large-format hospitals
Key Highlights
Guwahati hospital capacity increased by 62.5% from 400 beds to 650 beds
Estimated project cost for the Guwahati expansion stands at Rs 970 Cr
Standalone revenue for Q1 FY27 grew to Rs 1,078.7 Cr from Rs 882.1 Cr YoY
Total existing bed capacity reached 3,737 beds as of June 30, 2026
Final dividend of Rs 0.50 per share declared for FY26
👀 What to Watch
Monitor the execution and construction progress of the Guwahati facility over its 3-4 year phased timeline and track the occupancy ramp-up at the recently launched Noida facility.
Medanta expands Guwahati project to 650 beds; Rs 970 Cr investment; Q1 PAT at Rs 137 Cr
Global Health Limited (Medanta) reported Q1 FY27 standalone revenue of Rs 1,078.7 cr and a PAT of Rs 137.3 cr. A major highlight is the upward revision of the Guwahati hospital project, increasing planned capacity from 400 to 650 beds with an estimated investment of Rs 970 cr. This investment represents approximately 22% of the company's TTM revenue, signaling aggressive growth in the North East. The company also fixed August 14, 2026, as the record date for a Rs 0.50 per share final dividend.
Confidence: HIGH
What changedMedanta has significantly upsized its Guwahati greenfield project and reported steady Q1 earnings while appointing a new Chief Digital Officer.
Why it mattersThe capacity increase in Guwahati targets an underserved market of 50 million people, while the Rs 970 cr capex demonstrates strong balance sheet utilization for long-term scale.
Guwahati Project Investment: Rs 970 crInvestment vs TTM Revenue: ~22%Revised Guwahati Capacity: 650 bedsQ1 Standalone PAT: Rs 137.3 crDividend per share: Rs 0.50Dividend Record Date: August 14, 2026
📅 Short termThe stock may react positively to the capacity expansion news and the dividend record date announcement in the coming weeks.
📈 Long termThe expansion into Guwahati and other greenfield sites (Mumbai, Delhi) supports a structural growth narrative, aiming to add 2,000+ beds over the next few years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in greenfield hospital construction
- Regulatory risks associated with healthcare pricing
- High capital intensity of the expansion phase
Key Highlights
Guwahati hospital capacity increased by 62.5% from 400 beds to 650 beds
Estimated investment for the Guwahati project is Rs 970 cr, funded via internal accruals and debt
Standalone Q1 FY27 revenue grew to Rs 1,078.7 cr from Rs 882.2 cr in the same quarter last year
Final dividend of Rs 0.50 per equity share announced with a record date of August 14, 2026
Total existing bed capacity across the group stands at 3,737 as of June 30, 2026
👀 What to Watch
Watch for the execution timeline of the Guwahati project over the next 3-4 years and the impact of the new Chief Digital Officer on operational efficiencies and digital patient services.
Medanta Q1 Revenue up 22% YoY; Guwahati Hospital Capacity Expanded to 650 Beds
Global Health Limited (Medanta) reported a strong 22.3% YoY growth in standalone revenue to ₹1,078.72 Cr for Q1 FY27. A major highlight is the board's approval to upsize the upcoming Guwahati hospital from 400 to 650 beds, involving a ₹970 Cr investment. The company also declared a final dividend of ₹0.50 per share with a record date of August 14, 2026. Additionally, a new Chief Digital Officer was appointed to lead technology initiatives as the company scales its 3,737-bed existing network.
Confidence: HIGH
What changedMedanta has significantly increased the scale of its North-East expansion by adding 250 beds to the Guwahati project and reported robust double-digit revenue growth for the first quarter.
Why it mattersThe capacity increase in Guwahati targets an underserved market of 50 million people, while the ₹970 Cr investment demonstrates aggressive capital deployment for long-term growth.
Q1 Standalone Revenue: ₹1,078.72 CrGuwahati Project Cost: ₹970 CrProject Cost vs Net Worth: 24.17%Revised Guwahati Capacity: 650 bedsDividend per share: ₹0.50
📅 Short termThe stock is likely to react positively to the strong revenue growth and the increased scale of the Guwahati expansion project.
📈 Long termThe company is successfully executing its strategy to add 2,000+ beds, with the Guwahati expansion serving as a key regional hub for tertiary care over the next 4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk associated with the 3-4 year construction timeline for the Guwahati facility
- Potential margin pressure from increased finance costs if debt is heavily utilized for the ₹970 Cr capex
Key Highlights
Standalone revenue for Q1 FY27 reached ₹1,078.72 Cr, a 22.3% increase from ₹882.16 Cr in Q1 FY26.
Guwahati hospital capacity revised upward by 250 beds to a total of 650 beds.
Estimated investment for the Guwahati project is ₹970 Cr, representing approximately 24% of the company's current Net Worth.
Final dividend of ₹0.50 per equity share confirmed for FY25-26, payable within 30 days of AGM approval.
Total existing bed capacity across the group stands at 3,737 beds as of June 30, 2026.
👀 What to Watch
Investors should monitor the execution timeline of the Guwahati project over the next 3-4 years and the margin impact of the newly acquired Indore oncology facility.
650-Bed Guwahati Expansion Approved; Q1 Revenue Up 22% YoY to ₹1,079 Cr
Global Health (Medanta) reported a strong 22.3% YoY growth in standalone revenue to ₹1,078.7 cr for Q1 FY27. While Profit After Tax (PAT) declined 9.6% YoY to ₹137.3 cr, this was primarily due to a high base in the previous year which included exceptional gains. A major highlight is the board's approval to upsize the upcoming Guwahati hospital from 400 to 650 beds with a ₹970 cr investment. The company also fixed August 14, 2026, as the record date for a ₹0.50 per share final dividend.
Confidence: HIGH
What changedMedanta has significantly increased the scale of its Guwahati expansion and reported its Q1 FY27 financial performance, alongside appointing a new Chief Digital Officer.
Why it mattersThe expansion in Guwahati (₹970 cr) represents a major capital commitment (~22% of TTM revenue) that will drive long-term volume growth. Strong revenue growth in Q1 confirms robust demand for tertiary healthcare despite a slight dip in YoY PAT due to base effects.
Q1 Standalone Revenue: ₹1,078.7 crGuwahati Project Investment: ₹970 crInvestment vs TTM Revenue: ~22%Revised Guwahati Bed Capacity: 650 bedsFinal Dividend per Share: ₹0.50Existing Bed Capacity: 3,737 beds
📅 Short termThe stock may react positively to the strong top-line growth and the ambitious expansion plans, although the YoY PAT decline might be scrutinized by some investors.
📈 Long termThe company is aggressively executing its 2,000+ bed expansion strategy. Upsizing the Guwahati facility suggests a deeper focus on regional hubs, which should drive structural growth over the next 3-5 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the ₹970 cr greenfield project in Guwahati
- Potential margin pressure from rising finance costs and depreciation as new capacities come online
Key Highlights
Standalone revenue for Q1 FY27 increased 22.3% YoY to ₹1,078.7 cr from ₹882.2 cr
Guwahati hospital project capacity upsized by 62.5% to 650 beds with an estimated ₹970 cr investment
Existing operational bed capacity reached 3,737 beds as of June 30, 2026
Final dividend of ₹0.50 per share confirmed with record date set for August 14, 2026
Appointment of Pradeep Kumar Singh as Chief Digital Officer to lead technology and digital transformation
👀 What to Watch
Investors should monitor the execution timeline of the Guwahati project (3-4 years) and the occupancy ramp-up at the Noida facility. The upsized Guwahati project indicates strong management confidence in the North-East market demand.
Medanta Receives LOI for 150-Seat Medical College in Gurugram
Global Health Limited (Medanta) has received a Letter of Intent (LOI) from the Government of Haryana to establish a medical college at its flagship Gurugram facility. The college is sanctioned for 150 MBBS seats, marking the company's strategic entry into medical education. This initiative is designed to create a captive pipeline of high-quality clinical talent and strengthen the company's research and academic ecosystem. The development follows an earlier application made in March 2026, signaling a successful regulatory milestone.
Key Highlights
Received Letter of Intent (LOI) from the Medical Education & Research Department, Government of Haryana.
Approved for the establishment of a medical college with 150 MBBS seats.
Project to be located at Medanta – The Medicity, Sector-38, Gurugram.
Strategic move to ensure a continuous supply of trained clinical talent for the hospital chain.
Follows up on the company's initial application dated March 25, 2026.
👀 What to Watch
Investors should view this as a positive long-term strategic move that enhances Medanta's brand value and talent retention; monitor for future disclosures regarding capital expenditure and construction timelines.
Medanta FY26 Revenue Up 20% to ₹45,089 Mn; Plans ₹45,000 Mn Capex for 2,700 New Beds
Global Health (Medanta) reported a strong 20% YoY growth in total income to INR 45,089 million for FY26, with PAT rising 15.1% to INR 5,541 million. The company is aggressively expanding, with a planned capex of INR 45,000 million over five years to add approximately 2,700 beds across five greenfield projects. Operational efficiency improved as ARPOB grew 6.1% to INR 66,550 and ALOS reduced to 3.04 days. While the new Noida facility impacted overall margins with an EBITDA loss of INR 783 million, quarterly losses are narrowing as the hospital ramps up.
Key Highlights
Total income grew 20% YoY to INR 45,089 million, while PAT increased 15.1% to INR 5,541 million.
ARPOB increased by 6.1% to INR 66,550, supported by a 4% improvement in Average Length of Stay (ALOS) to 3.04 days.
Announced a massive expansion pipeline of 2,700 beds via 5 greenfield projects with a total capex of INR 45,000 million over 5 years.
International patient revenue grew by 33% YoY, now contributing 7% to the total revenue mix.
Board recommended a final dividend of INR 0.50 per share (25% of face value).
👀 What to Watch
Investors should focus on the company's ability to maintain high ARPOB and occupancy as it scales; the aggressive expansion plan signals strong long-term growth potential despite short-term margin pressure from new units.
Medanta FY26 Revenue Grows 20% to ₹4,509 Cr; EBITDA ex-Noida Up 19%
Global Health Limited (Medanta) reported a strong FY26 with total income rising 19.6% YoY to INR 45,089 million and PAT increasing 15.1% to INR 5,541 million. The company significantly expanded its capacity by adding 623 beds (20.5% growth), including the full operationalization of the 382-bed Noida facility. While the Noida unit reported an EBITDA loss of INR 783 million, startup losses are on a declining trend, and matured hospitals maintained steady growth. Operational metrics remained robust with a 16% increase in in-patient volumes and a 6.1% rise in ARPOB to INR 66,550.
Key Highlights
Consolidated Total Income grew 19.6% YoY to INR 45,089 million in FY26
EBITDA (excluding Noida) rose 18.6% to INR 11,343 million with a 25.7% margin
Total bed capacity increased by 20.5% with 623 additions, including 382 beds at the new Noida facility
In-patient and Out-patient volumes grew by 16.0% and 18.7% respectively, while ARPOB reached INR 66,550
Board recommended a final dividend of 25% on face value, amounting to INR 0.50 per share
👀 What to Watch
Investors should focus on the strong volume growth and aggressive capacity expansion across Noida, Patna, and upcoming projects in Guwahati and Varanasi. The stock remains a high-conviction play in the healthcare sector as new units move toward profitability and matured units maintain high margins.
Medanta FY26 PAT Up 15.1% to INR 5,541M; Q4 PAT Surges 39.7% with Strong Bed Expansion
Global Health (Medanta) reported a strong FY26 with total income rising 19.6% to INR 45,089 million and PAT growing 15.1% to INR 5,541 million. The fourth quarter was particularly robust, with PAT jumping 39.7% y-o-y to INR 1,417 million, driven by higher patient volumes and improved realizations. The company successfully operationalized its 382-bed Noida facility, which is seeing narrowing EBITDA losses, and added a total of 623 beds across its network during the year. Management has recommended a dividend of INR 0.50 per share and outlined an aggressive expansion plan to add approximately 2,700 beds over the next 3-4 years.
Key Highlights
FY26 Total Income grew 19.6% y-o-y to INR 45,089 million; Q4 Income hit record INR 11,958 million
Full-year PAT increased 15.1% to INR 5,541 million, while Q4 PAT surged 39.7% to INR 1,417 million
Operationalized 382 beds in Noida; total bed capacity increased by 20.5% y-o-y with 623 new beds added in FY26
ARPOB grew 6.1% y-o-y to INR 66,550, and International Patient Revenue rose 33.2% to INR 2,780 million
Aggressive expansion roadmap with ~3,200 total beds planned over the next 4 years across multiple cities including Mumbai and Delhi
👀 What to Watch
Investors should view the narrowing losses at the Noida facility and the massive 2,700-bed expansion pipeline as significant long-term growth catalysts. The strong Q4 performance and healthy ARPOB growth suggest the company is effectively scaling its high-margin tertiary care model.
Medanta FY26 Results: PAT Grows to ₹496 Cr; Final Dividend of ₹0.50 Recommended
Global Health Limited (Medanta) reported a 15.8% year-on-year growth in annual revenue, reaching ₹37,093.78 million for FY26. Net profit for the full year increased to ₹4,962.01 million compared to ₹4,615.28 million in the previous fiscal year. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer and General Counsel.
Key Highlights
Annual Revenue from operations grew 15.8% YoY to ₹37,093.78 million.
Net Profit (PAT) for FY26 increased to ₹4,962.01 million from ₹4,615.28 million in FY25.
Board recommended a final dividend of ₹0.50 per equity share of face value ₹2.
Q4 FY26 revenue stood at ₹9,606.29 million, up from ₹8,028.68 million in the same quarter last year.
Appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel.
👀 What to Watch
The steady growth in revenue and profitability confirms Medanta's strong market position; investors should hold for long-term healthcare sector exposure while monitoring the impact of new leadership on growth initiatives.
Medanta FY26 Standalone Net Profit Rises to ₹4,962 Million; Proposes ₹0.50 Final Dividend
Global Health Limited (Medanta) reported a robust performance for the fiscal year ended March 31, 2026, with standalone revenue from operations growing 15.8% YoY to ₹37,093.78 million. The company's standalone net profit for the full year increased to ₹4,962.01 million, up from ₹4,615.28 million in the previous fiscal. The Board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer.
Key Highlights
Standalone Revenue from operations for Q4 FY26 grew 19.6% YoY to ₹9,606.29 million.
Full-year FY26 Standalone Net Profit increased to ₹4,962.01 million compared to ₹4,615.28 million in FY25.
Board recommended a final dividend of ₹0.50 per equity share of face value ₹2 each.
Total Standalone Income for FY26 rose to ₹38,157.86 million from ₹32,949.55 million in the previous year.
Appointment of Kedar Ashok Apte as Chief Marketing & Growth Officer to drive expansion.
👀 What to Watch
Investors should take note of the steady double-digit revenue growth and the company's ability to maintain profitability despite rising employee costs. The stock remains a strong long-term play in the Indian healthcare sector given its brand equity and expansion focus.
Medanta FY26 Revenue Up 15.8% to ₹37,094 Mn; Announces ₹0.50 Dividend & Management Changes
Global Health Limited (Medanta) reported a steady financial performance for FY26, with annual revenue from operations growing 15.8% year-on-year to ₹37,093.78 million. Net profit for the full year increased to ₹4,962.01 million from ₹4,615.28 million in the previous fiscal year. The board has recommended a final dividend of ₹0.50 per equity share (25% of face value). Additionally, the company announced key leadership changes, including the appointment of a new Chief Marketing & Growth Officer and General Counsel to drive future expansion.
Key Highlights
Annual Revenue from operations increased 15.8% YoY to ₹37,093.78 million in FY26
Net Profit for FY26 rose to ₹4,962.01 million compared to ₹4,615.28 million in FY25
Recommended a final dividend of ₹0.50 per equity share of face value ₹2 each
Appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel
Q4 FY26 revenue stood at ₹9,606.29 million, up from ₹8,028.68 million in the same quarter last year
👀 What to Watch
Investors should take note of the consistent double-digit revenue growth and the dividend payout as a sign of financial health. Monitor how the new leadership in marketing and growth impacts the company's expansion strategy in the coming quarters.
Global Health (Medanta) to Host Q4 FY2026 Earnings Call on May 15, 2026
Global Health Limited (Medanta) has scheduled its earnings conference call for the fourth quarter and full year ended March 31, 2026, on May 15, 2026. The call will be led by top management, including CMD Dr. Naresh Trehan and CEO Pankaj Sahni, to discuss financial performance and growth outlook. As of December 31, 2025, the company maintained 3,579 installed beds across six operational hospitals. Investors will be looking for updates on the five upcoming hospital projects in Mumbai, Guwahati, Varanasi, and Delhi.
Key Highlights
Earnings conference call scheduled for May 15, 2026, at 2:00 PM IST.
Company operated 3,579 installed beds across 6 hospitals as of December 31, 2025.
Five upcoming hospitals currently in the pipeline for Mumbai, Guwahati, Varanasi, and Delhi.
Management team including CMD, CEO, and CFO will participate in the briefing.
The call is hosted by ICICI Securities to discuss Q4 and FY2026 annual results.
👀 What to Watch
Investors should attend the call to gain insights into the occupancy levels of existing hospitals and the specific commissioning timelines for the five new projects. Focus on management's guidance regarding ARPOB (Average Revenue Per Occupied Bed) and expansion margins.
Medanta to Acquire 80-Bed Cancer Hospital in Indore for Rs 30 Crore
Global Health Limited (Medanta) has signed a Business Transfer Agreement to take over an 80-bed cancer hospital in Indore for a consideration of Rs 30 crore. The facility is strategically located just 500 meters from Medanta's existing 175-bed multi-specialty hospital, allowing for significant operational synergies. This acquisition enables Medanta to launch a comprehensive oncology program in Indore, filling a previous gap in its specialty offerings. The move strengthens the company's footprint in Central India and is expected to optimize capacity utilization across its Indore campus.
Key Highlights
Acquisition of an 80-bed newly-built Cancer Care Hospital in Indore for Rs 30 crore
Facility is located 500 meters from the existing 175-bed Medanta Indore hospital
Acquisition includes the transfer of business as a going concern and assignment of a long-term lease
Enables the launch of a comprehensive oncology program to enhance high-margin specialty offerings
Medanta's total operational network reached 3,579 installed beds as of December 31, 2025
👀 What to Watch
Investors should view this as a strategic, low-cost expansion that enhances Medanta's service mix and regional market share. Monitor the impact on Average Revenue Per Occupied Bed (ARPOB) as the high-margin oncology services scale up.
Medanta to Acquire 79-Bed Cancer Hospital in Indore for ₹30 Crores
Global Health Limited (Medanta) has approved the acquisition of a 79-bedded oncology-focused hospital in Indore through a Business Transfer Agreement (BTA). The facility is strategically located just 500 meters from Medanta's existing Indore hospital, which is expected to drive significant operational synergies and fill a specialty gap in oncology. The acquisition cost is ₹30 crores, to be funded via internal accruals and debt, with completion expected by September 2026. This move expands Medanta's total capacity from its current base of 3,579 beds.
Key Highlights
Acquisition of a 79-bed specialized cancer care facility in Indore for ₹30 crores
Target facility is located 500 meters from the existing Medanta Indore hospital, enabling high synergy
Expands Medanta's total network capacity from 3,579 beds as of March 2026
Target hospital reported a turnover of ₹19.9 million for the financial year 2024-25
Transaction to be completed by September 30, 2026, funded through internal accruals and debt
👀 What to Watch
Investors should look favorably on this acquisition as it strengthens Medanta's regional dominance in Indore at a reasonable valuation. Monitor the post-acquisition integration and the impact on oncology-driven ARPOB (Average Revenue Per Occupied Bed).
Medanta to Acquire 79-Bed Cancer Hospital in Indore for Rs 30 Crore
Global Health Limited (Medanta) has entered into a Business Transfer Agreement to acquire a 79-bedded specialized cancer care hospital in Indore for Rs 30 crore. The facility is strategically located just 500 meters from Medanta's existing Indore hospital, which will enable significant operational synergies and fill a specialty gap in oncology. The acquisition will be funded through a mix of internal accruals and debt, with a target completion date before September 30, 2026. This move expands Medanta's total capacity, which stood at 3,579 beds as of March 31, 2026.
Key Highlights
Acquisition of a 79-bedded cancer care hospital in Indore for a cash consideration of Rs 30 crore.
Target facility is located 500 meters from the existing Medanta Indore facility, ensuring high synergy potential.
The target hospital reported a turnover of Rs 19.9 million for the financial year 2024-25.
Medanta's total network capacity reaches 3,658 beds following this acquisition (from 3,579 beds).
Transaction expected to close by September 30, 2026, funded via internal accruals and debt.
👀 What to Watch
Investors should look favorably on this acquisition as it strengthens Medanta's regional dominance in Indore at a relatively low cost per bed. Monitor the integration process and the subsequent improvement in the acquired facility's turnover and margins.
Medanta to Expand in UP with 400-Bed Varanasi Hospital and Rs 322 Cr Medical College
Global Health Limited (Medanta) has announced a significant expansion in Uttar Pradesh with a new 400-bed multi-specialty hospital in Varanasi. The project will follow a build-to-suit lease model where Medanta invests approximately Rs. 550 crores in medical equipment and interiors, while a partner develops the civil structure. Additionally, the company will invest Rs. 322 crores to establish a medical college directly under its corporate entity, leveraging revised NMC regulations. These projects, expected to be completed within four years, will strengthen Medanta's presence in the underserved Eastern UP market.
Key Highlights
Planned 400-bed multi-specialty hospital in Varanasi with an estimated investment of Rs. 550 crores by Medanta.
Approval for a new medical college with a project cost of Rs. 322 crores to be funded via internal accruals or debt.
Varanasi project to be executed via a lease agreement with Shripal Hospitality, reducing initial civil construction capex.
Total bed capacity in Uttar Pradesh to reach approximately 1,900 beds across Lucknow, Noida, and Varanasi.
Project completion for the Varanasi hospital is targeted within a 4-year timeframe.
👀 What to Watch
Investors should look favorably on this expansion as it targets a high-demand, underserved region using a capital-efficient lease model for the hospital building. Monitor the company's debt-to-equity ratio as it undertakes a combined investment of over Rs. 870 crores for these new ventures.
